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Approximately, 3-5% of girls and 1-2% of boys experience urinary tract infection (UTI) before puberty. Vesicoureteric reflux (VUR) is associated with higher rates (57%) of febrile 
UTI [1,2]. VUR is present in one-third of children presenting with 
febrile UTI and has been associated with a heightened risk of renal 
scarring [3]. The complex nature of the interaction between VUR 
and UTIs and their effects on the kidneys make the identification of 
those patients at risk for recurrent UTI and subsequent renal damage 
the biggest challenge in managing VUR.
Prediction of reflux resolution varies from patient to patient and 
may involve other factors than anatomic one. Once VUR has been 
diagnosed, the basic premise in management is to prevent further 
ascending UTI which may, if left untreated, lead to pyelonephritis 
which in turn, would lead to potential renal damage [4]. The 
potentially serious consequences at long term include hypertension 
and renal failure. The patients with VUR demonstrate a wide range 
of severity and a majority of reflux patients do not develop renal 
scars and probably will not need any intervention [5].
However, the role of antibiotic prophylaxis alone in these 
patients is still debatable when considering their efficacy in 
preventing recurrent UTI and renal scarring. The basis for 
antibiotic prophylaxis in patients with VUR was the fact that, 
ultimately, reflux in low Grades (I-III) was recognized to resolve 
over time and thus maintenance on low dose antibiotic would 
prevent or reduce the risk of UTI until such time that the reflux 
would disappear. Faster resolution of VUR is more likely in 
children who are aged <1 year at presentation, have a lower grade 
of reflux (Grades I-III), and have an asymptomatic presentation 
with prenatal hydronephrosis or sibling reflux [5].
Long-term requirement, questionable efficacy, potential 
side effects, allergic reactions, and antimicrobial resistance 
are few issues that make role of antibiotic prophylaxis in VUR 
questionable. Few trials have compared anti-reflux surgery with 
antimicrobial prophylaxis and showed no significant differences 
in the rates of recurrent UTI and renal scarring. Incidence of 
surgical management in these patients is showing a declining 
trend with more patients being managed conservatively. Here, we 
present our experience with conservative management of VUR 
with antibiotic prophylaxis over the last 2 years.
MATERIALS AND METHODS
This prospective observational study was carried out from June 
2014 to May 2016. Patients were enrolled in the study after 
ABSTRACT
Background: The management of vesicoureteric reflux (VUR) has undergone a radical change from initial ureteric reimplantation 
to a more conservative approach. Several studies have demonstrated the validity of this concept by evaluating the role of antibiotic 
prophylaxis. Recent randomized trials have shown no proven benefits of long-term antibiotic prophylaxis. Objective: The objective 
of this article is to review the outcome of conservative management of VUR with antibiotic prophylaxis over a period of 2-year. 
Materials and Methods: A prospective observational study for 2 years was performed in children with primary reflux. They were 
given continuous antibiotic prophylaxis and regularly followed up every 3 months. Relevant investigations were performed at 
every follow-up including monitoring of growth parameters. Outcome in terms of recurrent urinary tract infection (UTI) episodes, 
resolution of VUR, need for definitive surgery were analyzed. Results: Out of initial 48 patients enrolled in the study, three patients 
were lost for follow-up. Out of 45 patients (77 renal units), most of the patients had Grade III and IV reflux. Scarring was seen 
predominantly in Grade IV reflux (62.5%). At the end of 2 years, no units demonstrated Grade I reflux. Grade II reflux persisted in 
16.67%. Grade III reflux persisted in 23.68%, while Grade IV reflux persisted in 62.5%. Most of the fresh UTI episodes occurred in 
Grade III and IV VUR patients. Fresh renal scars were seen mostly in Grade IV group. One patient underwent ureteric reimplantation 
due to fresh renal scar and persistent reflux. Conclusions: Conservative management of VUR with antibiotic prophylaxis appears 
to be a suitable option without adverse outcomes. In the current scenario, surgery has a minor role to play in the treatment of VUR..
Key words: Vesicoureteric reflux, Antibiotic prophylaxis, Urinary tract infection
Vol 3 | Issue 4 | Oct - Dec 2016 Indian J Child Health 336
Murali et al. Medical management of primary vesicoureteric reflux
appropriate parental consent and ethical clearance was obtained 
from institutional ethics committee. Children from newborn 
period to 6-year of age, who were newly diagnosed with primary 
VUR between Grade I and IV VUR were included in the study. The 
patients who presented with UTI and whose ultrasound of kidney, 
ureter, and bladder (KUB) showing hydronephrosis or hydroureter 
were subjected to micturition cystourethrogram (MCU). Those 
patients with primary VUR were considered for the study. VUR 
was graded according to international classification [1].
Children with secondary reflux with congenital anomalies of 
urinary tract such as ureterocele, solitary kidney, ectopic or fused 
kidney, multicystic dysplastic kidney, and with renal insufficiency 
were excluded from the study. Furthermore, children more than 
6 years of age or with Grade V reflux and where parents refused to 
participate were excluded from the study. Patients’ demographic 
data including height/length, weight, and blood pressure were 
documented at diagnosis. Bowel and bladder habits were noted. 
Urine microscopy, renal function tests, ultrasound of KUB, and 
Technetium 99 dimercaptosuccinic acid (DMSA) scan were done 
as a baseline.
All patients received cephalexin prophylaxis single dose in 
the night daily as per the weight. Patients allergic to cephalexin 
received amoxicillin or trimethoprim-sulfamethoxazole as an 
alternative. Antibiotics were changed every 6 months to prevent 
the development of resistance and side effects (cephalexin to 
amoxicillin; amoxicillin to trimethoprim-sulfamethoxazole).
Patients were followed up every 3 months over the next 2-year 
period. At each follow-up, patients’ symptoms, if any, were 
recorded, and investigations such as urine routine/culture, renal 
function tests (urea, creatinine), and ultrasonography of KUB 
were performed. At the end of each year, MCU and Technetium 
99 DMSA scan were also performed for evaluation of reflux and 
scar status, respectively. Patients with culture-proven UTI were 
treated according to the sensitivity report. Primary outcome 
analysis on the number of UTI episodes, resolution of reflux, scar 
status, and the need for surgery was performed.
Statistical analysis for the study was performed using SPSS 
software (version 16.0, SPSS Inc, Chicago, IL). Kruskal–Wallis 
one-way analysis of variance was used to compare the categorical 
variables between groups. Unpaired t-test was used to analyze 
continuous variables between groups. All the values were 
expressed as mean±SD.
RESULTS
A total of 48 patients were included in the study, but three patients 
were lost to follow-up; hence, 45 patients were included in the 
analysis. Of these, 84.44% (n=38) were males and 15.56% 
(n=7) were females with male to female ratio of 5:1. Bilateral 
VUR was seen in 32 patients (71.11%) and was a more common 
in boys. The age of the youngest patient was 17 days, and the 
oldest patient was aged 42 months at diagnosis with a mean of 
10.3±2.8 months. These patients were diagnosed most commonly 
after an episode of UTI (n=33; 73.33%) followed by workup for 
antenatally detected hydronephrosis/hydroureter (n=11; 24.44%). 
Most UTIs were febrile at presentation (n=29) and more common 
in boys (n=21) than girls (n=8). There was no prior history of 
UTI in patients who were worked up for antenatally detected 
hydronephrosis/hydroureter. There was no evidence of growth 
impairment or hypertension in these patients to begin with.
The frequency of different grades of VUR according to 
International classification of reflux on MCU were: Grade I 
– 3 units, Grade II – 12 units, Grade III – 38 units, and Grade IV 
– 24 units. Baseline DMSA scans showed scarring in 12 patients 
(18 renal units) and all had a history of febrile UTI. The 
comparison between grade of VUR and incidence of scarring is 
depicted in Table 1. The highest incidence of scarring was noted 
in children with Grade IV reflux – 15 units (62.5%). No scarring 
was seen in Grade I or Grade II reflux groups.
Follow-up results at the end of 1 year and 2 years are 
summarized in Tables 2 and 3, respectively. No units demonstrated 
Grade I reflux at the end of 2 years. Grade II reflux persisted 
in two of 12 units (16.67%), Grade III in 23.68%, and Grade IV 
reflux persisted in 62.5% units. Most of the fresh UTI episodes 
occurred in Grade III and IV VUR patients. Fresh renal scars 
were seen mostly in Grade IV group. In one patient belonging to 
Grade IV group with fresh renal scar, surgery was considered due 
to persistent bilateral reflux (right Grade III and left Grade IV), 
same as that of the previous grade. None of the patients experienced 
growth retardation, deterioration in renal function or developed 
Table 1: Comparison between grade of MCU and scarring (baseline)
Grade on 
MCU
Number 
of units
Number of units showing 
scarring on DMSA scan
%
I 3 0 0
II 12 0 0
III 38 3 units 7.9
IV 24 15 units 62.5
MCU: Micturition cystourethrogram, DMSA: Dimercaptosuccinic acid
Table 2: Comparison at the end of 1-year follow-up
Grade 
on MCU
Number of 
units (old+new*)
Number of 
breakthrough 
UTI episodes
Number of 
units showing 
fresh scars
I 0 0 0
II 6+7 1 0
III 19+3 4 1 unit
IV 19 3 3 units
*Previously higher grade reflux which decreased in grade. MCU: Micturition 
cystourethrogram, UTI: Urinary tract infection
Table 3: Comparison at the end of 2-year follow-up
Grade 
on MCU
Number of 
units (old+new*)
Number of 
breakthrough 
UTI episodes
Number of 
units showing 
fresh scars
I 0 0 0
II 2+9 0 0
III 9+5 2 0
IV 15 3 2 units
*Previously higher grade reflux which decreased in grade. MCU: Micturition 
cystourethrogram, UTI: Urinary tract infection
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hypertension. None of our patients had constipation or bladder 
dysfunction. Circumcision was done in four boys due to recurrent 
UTI following which no further infections occurred.
DISCUSSION
VUR refers to retrograde flow of urine from the bladder into the 
ureter and collecting system of the kidney. It can be primary or 
secondary. The management of secondary VUR is directed at 
the cause rather than the reflux itself. Primary reflux is known 
to resolve over a period, and this fact forms the foundation for 
the basis of conservative management of primary VUR. VUR 
with UTI is known to produce renal damage. Identification of the 
patients at risk for recurrent UTI and subsequent renal damage 
remains a gray area in the management of VUR. VUR is present 
in one-third of children presenting with febrile UTI and has been 
associated with a heightened risk of renal scarring [1-3].
The somatic growth curve is one of the best global parameters 
of renal health in children and children with VUR and UTI, who 
fall below the third percentile, have shown catch up growth 
with successful suppression of pyelonephritis with continuous 
antibiotic prophylaxis or surgical correction of reflux. Hence, 
height and weight evaluation of these patients is necessary [2]. 
Patients with VUR demonstrate a wide range of severity, and a 
majority of reflux patients do not develop renal scars and probably 
will not need any intervention as shown in this study. Furthermore, 
the time bound factor associated with reflux resolution makes 
regular follow-up an essential part of management.
Antibiotic prophylaxis alone in these patients is still debated 
when considering their efficacy in preventing recurrent UTI 
and renal scarring. Faster resolution of VUR is more likely in 
children who are aged <1 year at presentation, have a lower grade 
of reflux (Grade I-III), and have an asymptomatic presentation 
with prenatal hydronephrosis or sibling reflux. Antibiotic 
prophylaxis is recommended regardless of VUR grade, renal 
scarring or symptoms in all children diagnosed within the first 
year of life [5]. Opponents of prophylaxis quote long-term 
requirement, questionable efficacy, side effects, allergic reactions 
and emergence of antimicrobial resistance as the criteria for 
not using antibiotics [6]. Few trials have compared anti-reflux 
surgery with antimicrobial prophylaxis and showed no significant 
differences in the rates of recurrent UTI and renal scarring.
Although the efficacy of antibiotic prophylaxis remains 
unproven, we have adopted to this measure mainly to assure 
regular follow-up and pacify the parents’ anxiety. Studies have 
shown that parents of children with VUR generally prefer 
antibiotic prophylaxis as the initial treatment modality [7,8]. 
The incidence of infection appears to be high in the groups 
with Grade III and IV reflux. Considering this fact studies have 
preferentially avoided prophylaxis in Grade I and II reflux with 
no detrimental effects [6,9,11]. This is also supported by the fact 
that low-grade reflux has higher and faster rates of resolution.
Another important factor, frequently associated with VUR and 
most frequently neglected also, is the presence of constipation 
and dysfunctional voiding. Constipation is proven to increase the 
incidence of symptomatic UTI and bacteriuria in patients with 
VUR. Females are more commonly affected by constipation and 
dysfunctional voiding. Constipation is also known to prolong the 
duration of resolution and reduce the resolution rates of reflux [12]. 
Lower urinary tract dysfunction (LUTD) was seen in 34% of 
children with VUR, and recurrent UTI was found in 33% children 
with LUTD according to the Swedish Reflux Trial [13]. Hence, 
bladder training and constipation treatment remain an integral 
part of VUR management. In our study, none of our patients had 
constipation as per history and X-ray abdomen done during MCU.
Incidence of surgical management in these patients is showing a 
declining trend with more patients being managed conservatively. 
In this study, only one patient required ureteric reimplantation for 
definitive management of VUR accounting for 2.22% of cases. 
Further, boys with recurrent UTI and high-grade VUR have been 
managed with circumcision with no further UTI episodes in our 
study. Circumcision is effective in reducing the risk of UTI as per 
meta-analysis of 12 studies by Singh-Grewal et al. by decreasing 
prepucial colonization [14]. Endoscopic subureteric injection 
therapy (STING) has become popular over the recent years as 
another alternative to conventional surgery. In a meta-analysis 
of endoscopic therapy, the reflux resolution rate after a single 
endoscopic treatment was 72% for Grade III, 63% for Grade IV, 
and 51% for Grade V [15]. It has inherent disadvantages of high 
cost, unknown long-term efficacy and lower resolution rates 
compared to open surgery. We have not employed STING in any 
of these patients owing to the cost and more, so we wanted to 
evaluate the role of conservative management in these patients. 
Hence, STING therapy was not considered.
CONCLUSION
Conservative management of VUR with antibiotic prophylaxis 
appears to be a suitable option without adverse outcomes. 
Prophylaxis may not be beneficial in low-grade reflux but it may 
help in allaying parents’ anxiety from the fact that something is 
being done for the child. In the current scenario, surgery has a 
minor role to play provided that the reflux is resolving with no 
fresh renal scars or growth impairment.
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